292 related articles for article (PubMed ID: 17706835)
1. Interleukin-12, interleukin-23, and psoriasis: current prospects.
Torti DC; Feldman SR
J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
3. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
[TBL] [Abstract][Full Text] [Related]
4. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
Griffiths CE; Girolomoni G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-23: a key cytokine in inflammatory diseases.
Duvallet E; Semerano L; Assier E; Falgarone G; Boissier MC
Ann Med; 2011 Nov; 43(7):503-11. PubMed ID: 21585245
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis.
Sonderegger I; Röhn TA; Kurrer MO; Iezzi G; Zou Y; Kastelein RA; Bachmann MF; Kopf M
Eur J Immunol; 2006 Nov; 36(11):2849-56. PubMed ID: 17039570
[TBL] [Abstract][Full Text] [Related]
8. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis.
Guan Q; Ma Y; Hillman CL; Ma A; Zhou G; Qing G; Peng Z
Vaccine; 2009 Nov; 27(50):7096-104. PubMed ID: 19786142
[TBL] [Abstract][Full Text] [Related]
9. Briakinumab.
Lima XT; Abuabara K; Kimball AB; Lima HC
Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977
[TBL] [Abstract][Full Text] [Related]
10. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
Chiricozzi A; Saraceno R; Chimenti MS; Guttman-Yassky E; Krueger JG
Expert Opin Ther Targets; 2014 May; 18(5):513-25. PubMed ID: 24568095
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet's disease.
Lew W; Chang JY; Jung JY; Bang D
Br J Dermatol; 2008 Mar; 158(3):505-11. PubMed ID: 18205865
[TBL] [Abstract][Full Text] [Related]
12. The potential of interleukin 12 inhibition in the treatment of psoriasis.
Rosmarin D; Strober BE
J Drugs Dermatol; 2005; 4(3):318-25. PubMed ID: 15898287
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model.
Nakajima K; Kanda T; Takaishi M; Shiga T; Miyoshi K; Nakajima H; Kamijima R; Tarutani M; Benson JM; Elloso MM; Gutshall LL; Naso MF; Iwakura Y; DiGiovanni J; Sano S
J Immunol; 2011 Apr; 186(7):4481-9. PubMed ID: 21346238
[TBL] [Abstract][Full Text] [Related]
14. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers -- IL-12, IL-18 and IL-23.
Piskin G; Tursen U; Sylva-Steenland RM; Bos JD; Teunissen MB
Exp Dermatol; 2004 Dec; 13(12):764-72. PubMed ID: 15560760
[TBL] [Abstract][Full Text] [Related]
15. Specific targeting of interleukin-23p19 as effective treatment for psoriasis.
Levin AA; Gottlieb AB
J Am Acad Dermatol; 2014 Mar; 70(3):555-61. PubMed ID: 24373779
[TBL] [Abstract][Full Text] [Related]
16. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M; Alwawi E; Gordon KB
Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
Lee E; Trepicchio WL; Oestreicher JL; Pittman D; Wang F; Chamian F; Dhodapkar M; Krueger JG
J Exp Med; 2004 Jan; 199(1):125-30. PubMed ID: 14707118
[TBL] [Abstract][Full Text] [Related]
19. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection.
Chackerian AA; Chen SJ; Brodie SJ; Mattson JD; McClanahan TK; Kastelein RA; Bowman EP
Infect Immun; 2006 Nov; 74(11):6092-9. PubMed ID: 16923792
[TBL] [Abstract][Full Text] [Related]
20. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
Ding C; Xu J; Li J
Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
